Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVOXAC vs ACHROMYCIN V
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.
Treatment of dry mouth symptoms in patients with Sjögren's syndrome,Off-label: Management of radiation-induced xerostomia
Infections caused by susceptible strains of bacteria including rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, and spirochetes,Acne vulgaris,Adjunctive therapy in severe acne,Off-label: Chronic prostatitis, sclerosing keratitis, rosacea
30 mg orally three times daily.
250-500 mg orally every 6 hours
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes N-oxidation and hydroxylation.
Not extensively metabolized; primarily excreted unchanged in urine via glomerular filtration; small amount metabolized in liver.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Approximately 50-60% bound to plasma proteins, primarily albumin.
50-65% bound to serum albumin; primarily binds to alpha-1-acid glycoprotein.
Volume of distribution is approximately 6 L/kg, indicating extensive distribution into tissues beyond plasma water.
1.5-2.0 L/kg (large volume indicates extensive tissue distribution, concentrating in bile, liver, kidneys, and bone; minimal CNS penetration despite lipophilicity).
Oral bioavailability is approximately 30% due to extensive first-pass metabolism.
Oral: 60-80% (reduced by food, particularly dairy products, due to chelation with divalent cations). Intravenous: 100%.
For GFR <30 m L/min: not recommended due to increased systemic exposure.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: 250-500 mg every 12-24 hours; GFR <10 m L/min: 250-500 mg every 24 hours
No adjustment required for mild to moderate hepatic impairment; not studied in severe impairment.
No dosage adjustment required; use with caution in severe hepatic impairment due to potential hepatotoxicity
Safety and efficacy not established; no recommended dose.
Children >8 years: 25-50 mg/kg/day orally divided every 6 hours
No specific dose adjustment; monitor for increased anticholinergic effects due to age-related reduced clearance.
Consider age-related renal impairment; adjust dose based on GFR; avoid if possible due to increased risk of photosensitivity and gastrointestinal effects
None.
Use during tooth development (last half of pregnancy, infancy, childhood to age 8 years) may cause permanent discoloration of teeth (yellow-gray-brown).
Cardiovascular effects: May cause bradycardia, AV block, hypotension; use caution in patients with cardiovascular disease.,Pulmonary effects: Can exacerbate asthma, chronic bronchitis, or COPD due to increased bronchial secretions.,Ophthalmic effects: May impair night vision or cause visual disturbances; caution when driving at night.,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Caution in moderate to severe hepatic disease.,Potential for sweating and dehydration: Monitor fluid intake.,Drug interactions: Concomitant use with beta-blockers or other cholinergic agents may increase risk of bradycardia.
Photosensitivity manifested by exaggerated sunburn reaction,Renal impairment may lead to drug accumulation and potential hepatotoxicity,Superinfection with resistant organisms including fungi,Bone growth retardation in premature infants,Pseudotumor cerebri (benign intracranial hypertension) in adults
Uncontrolled asthma,Narrow-angle glaucoma,Acute iritis,Hypersensitivity to cevimeline or any component,Concurrent use with certain anticholinergics (e.g., atropine) due to antagonistic effects
Hypersensitivity to tetracyclines,Pregnancy,Children under 8 years of age,Severe renal or hepatic impairment
No significant food interactions; may be taken with or without food. However, high-fat meals may delay absorption but not overall effect.
Avoid dairy products (milk, cheese, yogurt) and calcium-fortified foods within 2-4 hours of dosing. Also avoid concurrent intake of iron-rich foods or supplements, zinc, magnesium, and antacids. High-fat meals may reduce absorption; take on an empty stomach.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variations at doses 2-4 times the maximum recommended human dose. First trimester: Potential risk, use only if benefit justifies risk. Second trimester: Limited data, avoid unless necessary. Third trimester: No specific fetal risks identified, but monitor for maternal cholinergic effects.
Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Reversible inhibition of bone growth has been reported. First-trimester exposure is associated with a small risk of neural tube defects and other malformations in some studies. Avoid use during pregnancy unless for serious infections (e.g., anthrax, brucellosis) when alternative antibiotics are contraindicated.
Unknown if excreted in human breast milk. M/P ratio not available. Caution advised due to potential for cholinergic side effects in nursing infants. Consider discontinuing nursing or drug, taking into account importance of drug to mother.
Tetracycline is excreted into human milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.6–0.8. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. Short-term use at recommended doses is generally considered compatible with breastfeeding by the American Academy of Pediatrics, but prolonged or repeated courses should be avoided. Monitor infant for potential gastrointestinal disturbances or rash.
No specific pharmacokinetic studies in pregnancy. Pregnancy may alter drug absorption and metabolism; however, no established dose adjustments. Start at lowest effective dose (30 mg three times daily) and titrate based on response and tolerability. Monitor for reduced efficacy or increased toxicity due to pregnancy-induced changes.
Pregnancy reduces tetracycline serum concentrations due to increased volume of distribution and enhanced hepatic clearance. However, dose adjustments are not routinely recommended because the drug is generally avoided in pregnancy. If use is unavoidable (e.g., anthrax), standard adult doses (e.g., 250-500 mg every 6 hours) may be insufficient; consider monitoring serum levels if available and adjusting based on clinical response. Avoid in the second and third trimesters if possible.
EVOXAC (cevimeline) is a cholinergic agonist used primarily for xerostomia in Sjögren's syndrome; a key pearl is to avoid concurrent use with other parasympathomimetics due to additive effects. Monitor for excessive sweating, bradycardia, and bronchospasm, especially in patients with asthma or COPD. Contraindicated in uncontrolled asthma, iritis, and angle-closure glaucoma. Dose reduction may be required in renal impairment.
Tetracycline chelates with divalent and trivalent cations; avoid concurrent administration with dairy, antacids, iron, or calcium supplements. Photosensitivity risk: advise sun avoidance and use of sunscreen. Monitor renal function in elderly; adjust dose in severe renal impairment. Not for use in pregnancy or children under 8 years due to tooth discoloration and bone growth inhibition. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption.
Take exactly as prescribed, usually three times daily with or without food.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause blurred vision or dizziness.,Report excessive sweating, abdominal cramps, slow heart rate, or difficulty breathing to your healthcare provider immediately.,Do not use with other medications that increase saliva or tear production without consulting your doctor.,Store at room temperature away from moisture and heat.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium supplements within 2-4 hours of taking this drug.,Protect your skin from sun exposure; use sunscreen and wear protective clothing as this medicine can cause severe sunburn.,Do not take this drug if you are pregnant or breastfeeding; it can harm the baby's teeth and bones.,Complete the full course of treatment even if you feel better; do not skip doses.,Report any signs of allergic reaction, severe headache, blurred vision, or persistent diarrhea to your doctor immediately.,Store at room temperature away from moisture and light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVOXAC vs ACHROMYCIN V, answered by our medical review team.
EVOXAC is a Cholinergic Agonist that works by Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.. ACHROMYCIN V is a Tetracycline Antibiotic that works by Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVOXAC and ACHROMYCIN V depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVOXAC is: 30 mg orally three times daily.. The standard adult dose of ACHROMYCIN V is: 250-500 mg orally every 6 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVOXAC and ACHROMYCIN V in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVOXAC is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variatio. ACHROMYCIN V is classified as Category C. Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.